INO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
18.6M
-15.2%
21.9M
+25.6%
17.5M
-17.6%
21.2M
-8.1%
23.1M
R&D
10.8M
-23.1%
14.1M
+37.1%
10.3M
-23.0%
13.3M
-8.2%
14.5M
SG&A
7.8M
-1.0%
7.9M
+9.2%
7.2M
-8.4%
7.9M
-8.0%
8.6M
Operating Income
-18624522
+15.2%
-21949993
-25.6%
-17476601
+17.6%
-21210455
+8.1%
-23084519
EBITDA
-18302488
+15.4%
-21633149
-26.2%
-17136404
+17.9%
-20860257
+8.2%
-22728368
Net Income
-6012458
+69.5%
-19682798
-622.8%
3.8M
+108.3%
-45496672
-93.4%
-23519412
EPS (Basic)
$-0.07
+75.0%
$-0.28
-566.7%
$0.06
+106.9%
$-0.87
-42.6%
$-0.61
EPS (Diluted)
$-0.07
+75.0%
$-0.28
-566.7%
$0.06
+106.9%
$-0.87
-42.6%
$-0.61
Shares (Diluted)
81.6M
+18.1%
69.1M
+19.3%
57.9M
+11.0%
52.2M
+34.4%
38.8M
Inovio Pharmaceuticals (INO) โ€” Financials